Lyell Immunopharma Inc Ordinary Shares LYEL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if LYEL is a good fit for your portfolio.
News
-
Thinking about buying stock in Mediwound, AeroVironment, Airship AI, Lyell Immunopharma, or Sunshine Biopharma?
-
Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting
-
Thinking about buying stock in Intuitive Machines, Lyell Immunopharma, Hallador Energy, Eiger Biopharmaceuticals, or WEC Energy Group?
-
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023
-
Lyell Immunopharma Announces Participation in March Investor Conferences
Trading Information
- Previous Close Price
- $2.30
- Day Range
- $2.15–2.53
- 52-Week Range
- $1.32–3.97
- Bid/Ask
- $2.10 / $2.71
- Market Cap
- $560.86 Mil
- Volume/Avg
- 1 / 927,604
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 4,247.10
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 224
- Website
- https://www.lyell.com
Comparables
Valuation
|
Metric
|
LYEL
|
ITOS
|
SLRN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.85 | 0.66 | 0.69 |
Price/Sales | 4,247.10 | 30.01 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
LYEL
ITOS
SLRN
Financial Strength
|
Metric
|
LYEL
|
ITOS
|
SLRN
|
|---|---|---|---|
Quick Ratio | 15.82 | 13.46 | 8.53 |
Current Ratio | 16.07 | 13.76 | 8.65 |
Interest Coverage | — | — | — |
Quick Ratio
LYEL
ITOS
SLRN
Profitability
|
Metric
|
LYEL
|
ITOS
|
SLRN
|
|---|---|---|---|
Return on Assets (Normalized) | −20.62% | −12.92% | −57.50% |
Return on Equity (Normalized) | −23.35% | −14.67% | −88.66% |
Return on Invested Capital (Normalized) | −24.46% | −18.54% | −96.26% |
Return on Assets
LYEL
ITOS
SLRN
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Vthsnzfccm | Hvqy | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Fylqtksxk | Yfzdnw | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Wqfmsqvqc | Hpjsqm | $97.8 Bil | |
MRNA
| Moderna Inc | Dxvhmxkn | Htlp | $38.8 Bil | |
ARGX
| argenx SE ADR | Lkwwlxl | Zwzsv | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Yqtsnrwf | Qbs | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Nflrrfwr | Jkgnpk | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Dbvycwwfm | Vyqcbwg | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Stfynhtzt | Myvlpfr | $12.5 Bil | |
INCY
| Incyte Corp | Jsnwwvg | Wndpbl | $11.5 Bil |